Cargando…

Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis

BACKGROUND: Uterine fibroids are benign. They belong to the category of “abdominal mass” in traditional Chinese medicine, and pathogenesis is mainly caused by weakness of the body, qi stagnation, and blood stasis. Drug therapy is the preferred treatment of uterine fibroids in clinical practice, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Chenhao, Qiao, Mingqi, Jia, Yuqi, Wang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542145/
https://www.ncbi.nlm.nih.gov/pubmed/34678886
http://dx.doi.org/10.1097/MD.0000000000027523
_version_ 1784589380121264128
author Bi, Chenhao
Qiao, Mingqi
Jia, Yuqi
Wang, Haijun
author_facet Bi, Chenhao
Qiao, Mingqi
Jia, Yuqi
Wang, Haijun
author_sort Bi, Chenhao
collection PubMed
description BACKGROUND: Uterine fibroids are benign. They belong to the category of “abdominal mass” in traditional Chinese medicine, and pathogenesis is mainly caused by weakness of the body, qi stagnation, and blood stasis. Drug therapy is the preferred treatment of uterine fibroids in clinical practice, and mifepristone is the most commonly used drug. In the past decade, a large number of clinical randomized controlled trials have proven that Chinese patent medicine combined with mifepristone in the treatment of uterine fibroids has a better curative effect, fewer adverse reactions, and higher safety than mifepristone alone. However, there is a lack of evidence-based research. This study aims to integrate clinical data through network meta-analysis to provide more evidence-based medical evidence for clinical medication. METHODS: The comprehensive search included Chinese and other-language databases, such as MEDLINE (PubMed), Web of Science, The Cochrane Library, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, China Scientific Journal Database, and China Biomedical Literature Database. Clinical randomized controlled trials of 6 Chinese patent medicines combined with mifepristone for the treatment of uterine fibroids, including Guizhi Fuling Capsule, Gongliuxiao Capsule, Gongliuqing Capsule, Danbie Capsule, Gongliuning Capsule, and Xiaojiean Capsule were retrieved. The search period was from January 2010 to April 2021. Two researchers screened the literature through EndNote and used Excel to extract data. RevMan 5.3 was used to evaluate the quality of the literature. Treatment measures were analyzed in R language, and a forest map and probability ranking map of various interventions were drawn. The network evidence map and correction comparison funnel map of various interventions were drawn by STATA 14.0 software. RESULTS: This study provides the clinical efficacy and safety of network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids will be systematically evaluated or descriptively analyzed. CONCLUSION: This study's purpose is to provide a reference for the clinical treatment of uterine fibroids to choose more effective intervention therapies.
format Online
Article
Text
id pubmed-8542145
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85421452021-10-25 Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis Bi, Chenhao Qiao, Mingqi Jia, Yuqi Wang, Haijun Medicine (Baltimore) 3800 BACKGROUND: Uterine fibroids are benign. They belong to the category of “abdominal mass” in traditional Chinese medicine, and pathogenesis is mainly caused by weakness of the body, qi stagnation, and blood stasis. Drug therapy is the preferred treatment of uterine fibroids in clinical practice, and mifepristone is the most commonly used drug. In the past decade, a large number of clinical randomized controlled trials have proven that Chinese patent medicine combined with mifepristone in the treatment of uterine fibroids has a better curative effect, fewer adverse reactions, and higher safety than mifepristone alone. However, there is a lack of evidence-based research. This study aims to integrate clinical data through network meta-analysis to provide more evidence-based medical evidence for clinical medication. METHODS: The comprehensive search included Chinese and other-language databases, such as MEDLINE (PubMed), Web of Science, The Cochrane Library, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, China Scientific Journal Database, and China Biomedical Literature Database. Clinical randomized controlled trials of 6 Chinese patent medicines combined with mifepristone for the treatment of uterine fibroids, including Guizhi Fuling Capsule, Gongliuxiao Capsule, Gongliuqing Capsule, Danbie Capsule, Gongliuning Capsule, and Xiaojiean Capsule were retrieved. The search period was from January 2010 to April 2021. Two researchers screened the literature through EndNote and used Excel to extract data. RevMan 5.3 was used to evaluate the quality of the literature. Treatment measures were analyzed in R language, and a forest map and probability ranking map of various interventions were drawn. The network evidence map and correction comparison funnel map of various interventions were drawn by STATA 14.0 software. RESULTS: This study provides the clinical efficacy and safety of network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids will be systematically evaluated or descriptively analyzed. CONCLUSION: This study's purpose is to provide a reference for the clinical treatment of uterine fibroids to choose more effective intervention therapies. Lippincott Williams & Wilkins 2021-10-22 /pmc/articles/PMC8542145/ /pubmed/34678886 http://dx.doi.org/10.1097/MD.0000000000027523 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 3800
Bi, Chenhao
Qiao, Mingqi
Jia, Yuqi
Wang, Haijun
Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title_full Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title_fullStr Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title_full_unstemmed Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title_short Network meta-analysis of 6 kinds of Chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: A protocol for systematic review and network meta-analysis
title_sort network meta-analysis of 6 kinds of chinese patent medicines combined with mifepristone in the treatment of uterine fibroids: a protocol for systematic review and network meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542145/
https://www.ncbi.nlm.nih.gov/pubmed/34678886
http://dx.doi.org/10.1097/MD.0000000000027523
work_keys_str_mv AT bichenhao networkmetaanalysisof6kindsofchinesepatentmedicinescombinedwithmifepristoneinthetreatmentofuterinefibroidsaprotocolforsystematicreviewandnetworkmetaanalysis
AT qiaomingqi networkmetaanalysisof6kindsofchinesepatentmedicinescombinedwithmifepristoneinthetreatmentofuterinefibroidsaprotocolforsystematicreviewandnetworkmetaanalysis
AT jiayuqi networkmetaanalysisof6kindsofchinesepatentmedicinescombinedwithmifepristoneinthetreatmentofuterinefibroidsaprotocolforsystematicreviewandnetworkmetaanalysis
AT wanghaijun networkmetaanalysisof6kindsofchinesepatentmedicinescombinedwithmifepristoneinthetreatmentofuterinefibroidsaprotocolforsystematicreviewandnetworkmetaanalysis